Evidence map›Paper›PMID 34185197›Full record

ReviewCurrent treatment options in oncology2021

Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.

Mohammed Dawod, Teresa Alonso Gordoa, Mauro Cives, Louis De Mestier, Joakim Crona, Francesca Spada, Kjel Oberg, Marianne Pavel, Angela Lamarca

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 6 countries.

Mohammed DawodDepartment of Medical Oncology, ENETs, Centre of Excellence, The Christie NHS Foundation Trust, Manchester, UK.ORCID 0000-0002-4980-1883
Teresa Alonso GordoaDepartment of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Mauro CivesDepartment of Medical Oncology, University of Bari, Bari, Italy.
Louis De MestierDepartment of Gastroenterology, Beaujon Hospital, Université de Paris, Clichy, France.
Joakim CronaDepartment of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Francesca SpadaGastrointestinal Medical Oncology and Neuroendocrine Tumors Unit, European Institute of Oncology, Milan, Italy.
Kjel ObergDepartment of Endocrinology, Universitatsklinikum Erlangen, Erlangen, Germany.
Marianne PavelDepartment of Medical Oncology, ENETs, Centre of Excellence, The Christie NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, UK.
Angela LamarcaThe Christie NHS Foundation Trust, Wilmslow Road, M20 4BX, Manchester, UK. angela.lamarca@nhs.net.
The Christie NHS Foundation Trust · GBEuropean Institute of Oncology · ITHospital Universitario Ramón y Cajal · ESUniversitätsklinikum Erlangen · DEUniversité Paris Cité · FRUniversity of Bari Aldo Moro · ITUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementNeuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with rising incidence and prevalence. Outcome and therapy of small bowel neuroendocrine tumours (SBNETs) is variable, depending on the grade, differentiation, tumour burden, as well as the site of the tumour origin. Because of this, multidisciplinary approach is essential. Large randomized clinical trials, with somatostatin analogues (PROMID, CLARINET) or with peptide receptor radionuclide therapy (PRRT) with 177-lutetium (NETTER-1 trial) as well as the mammalian target of rapamycin inhibitor (mTOR) everolimus (RADIANT trials), represent milestones for the medical management of unresectable grade 1 and 2 SBNETS over the last decade. Novel therapies, such as tyrosine kinase inhibitors (TKI), are on the cutting edge. However, multiple unsolved questions remain. This review provides a comprehensive review of the main systemic therapeutic options for advanced SBNETs and discusses the latest guideline recommendations for palliative treatment.

Indexed as

Clinical Trials as TopicEverolimusHumansIntestinal NeoplasmsIntestine, SmallNeuroendocrine TumorsPalliative CarePractice Guidelines as TopicSomatostatinEverolimusSomatostatinProgressionPRRTSmall bowel neuroendocrine tumourSomatostatin analogueThird-line treatmentWell-differentiated

Identifiers

PMID34185197
OpenAlexW3175077457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.